Par sees sales gains across all sectors
WOODCLIFF LAKE, N.J. — Generic drug maker Par Pharmaceutical Cos. had sales of $227 million during fourth quarter 2010 and $1 billion for the year as a whole, according to an earnings statement Thursday.
Profits were $17.5 million for the quarter and $92.7 million for the year, compared with $10.7 million in fourth quarter 2009 and $76.9 million for 2009 as a whole.
Leading products for the year included metoprolol succinate, a generic version of AstraZeneca’s high blood pressure treatment Toprol XL, which had sales of $73 million for the quarter and $473.2 million for the year; as well as sumatriptan, a generic version of GlaxoSmithKline’s migraine treatment Imitrex, which had sales of $19.9 million during the quarter and $73 million for the year as a whole.
Among branded products, the breast cancer treatment Megace ES (megestrol) had sales of $14.8 million for the quarter and $60.9 million for the year, while the vitamin B12 deficiency treatment Nascobal B12 (cyanocobalamin) nasal spray had sales of $4.8 million for the quarter and $17.7 million for the year.
Novo Nordisk develops treatment for rarest bleeding disorder, seeks FDA approval
PRINCETON, N.J. — Novo Nordisk has filed for approval of a treatment for a rare genetic bleeding disorder, the Danish drug maker said Wednesday.
The company submitted to the Food and Drug Administration its application for recombinant factor XIII compound, for congenital factor XIII deficiency. Current treatments for FXIII deficiency use products derived from human blood plasma, which carries the risk of contamination.
Congenital factor XIII deficiency is considered the rarest bleeding disorder, with only 600 people diagnosed worldwide. Patients with the disease, which results from a lack of the protein clotting factor XIII, have a lifelong susceptibility to bleeding problems, including spontaneous hemorrhages in the brain.
Takeda seeks FDA approval for hypertension treatment
OSAKA, Japan — Drug maker Takeda has filed for regulatory approval of a drug to treat hypertension, the company said Wednesday.
Takeda announced that it had submitted an application with the Food and Drug Administration for the fixed-dose drug azilsartan medoxomil and chlorthalidone. Azilsartan medoxomil is an angiotensin II receptor blocker, or ARB, that lowers blood pressure by blocking the angiotensin II hormone.
“Millions of patients with hypertension do not have their condition under control,” said Darryl Sleep, VP clinical science at Takeda Global Research and Development Center. “We believe this compound, the first [in the United States] to combine an ARB with chlorthalidone, could potentially provide an important new treatment option for patients with hypertension and the healthcare providers who manage them.”